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Abstract
Introduction. Metabolic syndrome (MetS) is a risk factor for cardiovascular disease, and may be diagnosed in one in 
four adults worldwide. Since sexual dysfunction may occur in as many as 19–63% females, the following issues were 
addressed in the presented study: 1) Is there a relationship between metabolic syndrome and sexual disorders in female 
patients with MetS? 2) What is the potential impact of diet on occurrence of female sexual dysfunction?
Material and methods. The study involved 99 regularly menstruating women, of which 71 patients were diagnosed 
with metabolic syndrome (those were assigned to study group), and 28 patients did not have metabolic abnormalities 
(control group). All subjects underwent physical examination, including basic anthropometric measurements, and bio-
chemical blood tests were performed. Dietary intake was analyzed quantitatively and qualitatively using a three-day 
dietary recall. Participants were also asked to fill in questionnaires concerning their sexual life, and overall quality of life.
Results. There were no age differences between the groups. Number of meals per day was lower, and total caloric value 
was higher in MetS group. Women with metabolic syndrome were less sexually active, and found themselves less se-
xually attractive as compared to control group. In the MetS group, Mell-Krat SFM score was lower than in control group 
(44.6 ± 12.5 vs. 56.2 ± 5.7, p < 0.001), which indicated a higher incidence of female sexual dysfunction. Similar results 
were found using FSFI Scale (23.4 ± 10.4 vs. 28.3 ± 7.8, p = 0.005). Evaluation with SF-36 quality of life questionnaire 
showed no differences between the groups.
Conclusions. 1. The number of meals per day is lower, but the total dietary caloric value is higher in women with meta-
bolic syndrome than in control group not having MetS. 2. Women with metabolic syndrome are less sexually active, and 
have less satisfactory sexual relations than healthy females. 3. There is no difference in quality of life between women 
with and without metabolic syndrome. 4. Dietary habits have no impact on overall quality of life, quality of sexual life or 
occurrence of sexual disorders.
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Introduction
Metabolic syndrome (MetS) consists of various coinciding 
and interrelated metabolic conditions, which increase 
the risk of developing type 2 diabetes and cardiovascu-
lar disease. One in four adults worldwide (of more than 
20 years of age) has MetS, according to data from litera-
ture. In United States, up to 34% of general population 
fulfills the diagnostic criteria of MetS according to ATPIII 
and AHA/NHBLI definitions [1]. The WOBASZ study in 
Poland revealed that 21.7% men and 25.5% women in 
the analyzed population fulfilled IDF criteria for metabolic 
syndrome diagnosis [2]. In Japan, researchers could iden-
tify 7.8% persons with MetS using the same criteria [3]. 
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Metabolic syndrome increases the risk of cardiovascular 
disease but also contributes to development of endocrine 
conditions, including type 2 diabetes as well as gastrointe-
stinal disease, malignancy, depressive disorders, chronic 
renal disease, and sexual disorders [4–6]. The issues 
of sexual health, and its impact on quality of life have 
recently become subjects of debate. Sexual dysfunction 
is being investigated and addressed predominantly in 
men, who often suffer from erectile dysfunction related 
to cardiovascular disease [7]. Issues of female sexual life 
have not come to the spotlight as yet. However, female se-
xual dysfunction is not a negligible problem, and requires 
more study. It is estimated that sexual dysfunctions affect 
19–63% women worldwide, and some authors suggest 
the prevalence may be up to 71% in general population. 
In USA, this kind of dysfunction occurs in 25–63% women 
[8]. Hayes et al. [9] identified 11 of 1,248 studies concer-
ning this issue, and found out that 64% women (16–75%) 
suffered from diminished desire, 35% (16–48%) had orga-
smic difficulty, 31% (12–64%) hade arousal difficulty, and 
26% (7–58%) experienced pain. The report on sexuality 
in Poles (Raport Seksualność Polaków) by Lew-Starowicz 
[10] points out that decreased sexual needs concern 25% 
Polish women, 20% experience difficulties of arousal, 17% 
have too seldom orgasm, and 8% have no orgasm at all. 
Dyspareunia was reported by 13% Polish females, and 
vaginismus by 2% women. The issue of female sexuality 
is a complex one, which makes the study on problems 
underlying sexual dysfunction particularly challenging. 
Psychological factors are named in first place, and other 
issues include age, partner-related problems, lower 
socioeconomic status, lower education, chronic disease 
(diabetes, dyslipidemia, metabolic syndrome, ischaemic 
heart disease, overweight or obesity, uncompensated 
thyroid disorders). Other possible causative factors that 
should be named include previous physiological labors, 
abortions, pelvic dysfunction, depressive disorders, pre-
vious negative sexual experience, tobacco smoking, and 
medication with antihistaminic agents, antiepileptics, 
anxiolytics, antidepressants, hormonal contraception, 
hormonal replacement therapy, antiandrogens, antiestro-
gens or malignancy treatments [11–13]. Risk factors of 
female sexual dysfunction include cardiovascular disease 
and predisposing conditions such as metabolic syndro-
me (MetS). Prophylaxis and treatment of MetS begins 
with non-pharmacological measures, including dietary 
modification.
The presented study was aimed to analyze prevalence 
of sexual dysfunction in regularly menstruating women, and 
to investigate aspects of sexuality in women with metabolic 
syndrome as compared women with normal metabolic 
function. Furthermore, impact of diet on quality of sexual 
life, and issues of quality of life were investigated.
Material and methods
Analysis included 99 women with regular menstrual cycles. 
Patients presented various levels of education, sexual 
activity, and different marital status. Of those, 71 females 
were included in the study group, and 28 in the control 
group. Women in study group fulfilled criteria of metabolic 
syndrome according to IDF, NHLBI, AHA, WHF, IAS, and IASO 
2009 [14]. Inclusion criteria were the following: giving in-
formed consent to participation in the study, having regular 
menses, age ≥ 25 years, no psychic disorders (untreated 
or on specialist treatment), no major disease of adverse 
prognosis, not taking libido-affecting medication such as 
sedatives, psychotropic medication, oral contraception or 
antihistaminics. Women who fulfilled diagnostic criteria of 
metabolic syndrome were allocated to study group, whereas 
women in control group did not have MetS. Subjects not 
meeting the above described criteria were not included.
During the first appointment, anamnesis was taken, 
and physical examination performed, including measuring 
basic anthropometric parameters and arterial pressure. 
From each patient a blood sample was taken for evaluation 
of total cholesterol level as well as high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL) cholesterol, triglyce-
rides, fasting glucose, and high sensitivity C-reactive protein 
test (hs-CRP). The patients were instructed to take detailed 
dietary records for three consecutive days. Following the 
first appointment, the obtained clinical data were used 
for allocation to study or control group. During the second 
appointment, detailed dietary anamnesis was taken, and 
the patients were asked to fill in questionnaires concerning 
sexual needs and reactions. Instruments used included 
SFK/K Scale, Polish version of Mell-Krat Scale, commonly 
used in literature; Female Sexual Function Index (FSFI), 
a standardized questionnaire validated for use in Poland, 
evaluating satisfaction of sex life, level of sexual activity, 
partner relations and attitude to own femininity; and Short 
Form-36 (SF-36), standardized questionnaire evaluating 
quality of life, validated for use in Poland.
Results
There were no significant differences as to patient age 
and parity between the groups. Differences were, however, 
observed in anthropometric parameters (Table 1), bioche-
mical test results, and arterial pressure, as intended in the 
study protocol (Table 2).
Analysis of dietary recall data revealed that women in 
study group had fewer meals per day but their meals had 
a significantly greater total caloric value (TCV) than those 
reported by subjects in control group. Energy intake from 
carbohydrates was slightly greater in study group, whereas 
energy consumption from proteins was significantly grea-
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Table 1. Characteristics of study population
Parameter Study group Control group p value (Mann-Whitney U 
test)Mean value ± SD Mean value ± SD
Age (years) 40 ± 7 38 ± 6 NS
Parity 2 ± 1 1 ± 1 NS
Body mass [kg] 93 ± 16 83 ± 19 0.004
BMI [kg/m2] 34.7 ± 5.2 30.1 ± 6.7 0.0003
Waist circumference [cm] 102 ± 11 92 ± 15 0.0002
Hip circumference [cm] 115 ± 11 110 ± 12 0.0112
WHR 0.9 ± 0.1 0.8 ± 0.1 0.0005
SD — standard deviation; p — level of significance; NS — not statistically significant; BMI — body mass index; WHR — waist-to-hip ratio
Table 2. Test results in study population
Parameter Study group, mean value ± SD Control group, mean value ± SD p value*
Systolic BP [mm Hg] 135.3 ± 12.0 117.9 ± 14.0 < 0.001
Diastolic BP [mm Hg] 85.5 ± 9.1 78.2 ± 10.2 < 0.001
TC [mg/dl] 193.3 ± 35.2 181.2 ± 25.4 NS
HDL [mg/dl] 53.9 ± 15.1 68.1 ± 14.5 < 0.001
LDL [mg/dl] 111.3 ± 30.3 97.9 ± 21.8 0.049
TG [mg/dl] 140.7 ± 63.0 75.5 ± 25.8 < 0.001
Fasting glucose [mg/dl] 97.8 ± 11.2 89.4 ± 6.2 < 0.001
*Level of statistical significance was adopted at p < 0.05; SD — standard deviation; p — level of significance; BP — arterial blood pressure; TC — total cholesterol; NS — not statistically significant;  
HDL — high-density lipoprotein cholesterol; LDL — low-density lipoprotein cholesterol; TG — triglycerides
ter in the same group. Total consumption of fats and fat 
variants, excluding n-3 fats, was not significantly different 
between the groups (Table 3).
Fewer patients in study group had a regular sexual 
partner (82% vs. 96%, p = 0.07), and were significantly 
less often sexually active (69% vs. 89%, p < 0.05). More 
females in control group described physical contact with 
their partners during the last year as “very nice” (57% 
vs. 31%, p < 0.05). Patients in study group more often 
described their physical contacts as “quite nice” (27% vs. 
11%, p < 0.05) or “not really nice” (7% vs. 0%, p > 0.05). 
Significantly more respondents in control group stated 
that number of sexual contacts during the last year was 
satisfactory for them (82% vs. 51%, p < 0.05). On the 
contrary, women in study group thought they had too few 
intercourses (35% vs. 14%, p < 0.05).
Significantly more patients in study group did not 
express their opinion on own femininity and sexual attra-
ctiveness as compared to control group (49% vs. 21%, 
p = 0.01), whereas in the latter group more respondents 
felt truly feminine, and declared no sexual problems (61% 
vs. 23%, p = 0.0003). Besides, patients in control group 
more often declared having no sexual dysfunction (82% vs. 
59%, p < 0.05). When asked about occurrence of particular 
sexual problems (Fig. 1), subjects in study group more often 
responded positive. These were decreased sexual needs 
(44% vs. 14%, p < 0.05), having fewer orgasms (23% vs. 
7%, p > 0.05), not having orgasms (7% vs. 0%, p > 0.05), 
having problems with lubrication (8% vs. 4%, p > 0.05) or 
experiencing pain (8% vs. 4%, p > 0.05).
Analysis of data concerning sexual functions revealed 
significantly lower global FSFI score in study group when com-
pared to control group (23.4 ± 10.4 vs. 28.3 ± 7.8, p = 0.005). 
Patients in study group had both lower global score, and lower 
scores for respective domains, which were summed up for 
calculation of the global score. Significant differences were 
found for desire, arousal, and lubrication domains (Table 4).
Patients in study group had lower Mell-Krat scores for 
sexual needs and reactions when compared to patients 
in control group (44.6 ± 12.5 vs. 56.2 ± 5.7, p < 0.001), 
which reflects a higher prevalence of sexual dysfunction 
in MetS patients. Quality of life assessment using SF-
36 showed no significant difference as to the global score 
(Table 5), which was 56.0 ± 25.1 points in study group, 
and 46.5 ± 18.7 points in control group. Significant dif-
ference was observed in scores for physical functioning, 
with lower scores reflecting worse function in patients with 
metabolic syndrome.
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Figure 1. Answers to the question “Which of the following sexual problems concern yourself?” — comparison of study group and control 
group, *p < 0.05
Table 3. Total caloric value, number and composition of meals in study group versus control group
Parameter Study group Control group p value (Mann-Whit-
ney U test)*Mean value ± SD Median value Mean value ± SD Median value
Number of meals  
per day
3.7 ± 0.6 3.7 4.3 ± 0.5 4.3 0.00002
TCV per day (kcal) 1959 ± 501 1955.7 1556 ± 219 1577.2 0.00003
TCV from proteins [%] 16.6 ± 5.8 15.6 18.4 ± 4.3 17.4 < 0.05
TCV from carbohydrates 
[%]
51.7 ± 7.9 52.7 50.4 ± 6.7 49.6 NS
TCV from fats [%] 31.5 ± 6.5 30.7 31.8 ± 5.6 31.8 NS
TCV from saturated 
fats [%]
11.7 ± 3.5 11.5 11.0 ± 3.1 10.1 NS
TCV from monounsatu-
rated fats [%]
12.8 ± 4.0 12,0 12,1 ± 2,2 12,0 NS
TCV from polyunsatura-
ted fats [%]
4.8 ± 2.0 4.5 5.4 ± 2.0 4.6 NS
TCV from n-6 fats [%] 4.0 ± 1.8 3.6 4.4 ± 1.8 3.8 NS
TCV from n-3 fats [%] 0.8 ± 0.4 0.7 1.1 ± 0.5 1.0 0.01
n-6/n-3 ratio 6.3 ± 3.0 5.8 5.8 ± 3.6 4.6 NS
*Level of statistical significance was adopted at p < 0.05; SD — standard deviation; p — level of significance; TCV — total caloric value; NS — not statistically significant
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Discussion
Presented study revealed that women with metabolic syn-
drome more often have sexual dysfunction, poorer quality 
of sexual life, worse opinion of themselves as females 
and sexual partners as compared to healthy counterparts. 
Greater prevalence of sexual dysfunction in females with 
metabolic syndrome was reflected by lower Mell-Krat scores 
and FSFI scores in subjects with MetS. Esposito et al. [15] 
in their study also used FSFI scale for evaluation of sexual 
activity in women with metabolic syndrome, and found that 
patients with MetS had significantly lower scores as compa-
red to control group (23.2 ± 5.4 vs. 30.1 ± 4.7, p < 0.001). 
Therefore, a greater prevalence of sexual dysfunction 
could be confirmed in women with MetS. Ponholzer et al. 
[16] reported correlation between metabolic syndrome 
and worse quality of sexual life. Patients with MetS, both 
pre- and postmenopausal, more often complained of se-
xual dysfunction due to pain during intercourse, orgasm 
difficulties, and decreased desire, having fewer and less 
satisfactory intercourses than control subjects. However, 
statistically significant difference was observed only in 
the latter domain. Postmenopausal women had more 
problems with arousal, and reported lower impact of sex 
life on their overall quality of life. On the contrary, Kim et 
al. [17] found no correlation between occurrence of sexual 
dysfunction and metabolic syndrome in women. These 
authors observed no significant difference in occurrence 
of female sexual dysfunction (FSD) in patients having me-
tabolic syndrome as compared to healthy subjects (52.1% 
Table 5. Quality of life in premenopausal women with metabolic syndrome (MetS) as compared to premenopausal patients without MetS
Category Study group Control group p (Mann-Whitney  
U test)*Mean value ± SD Median value Mean value ± SD Median value
Physical functioning 11.4 ± 8.5 11.0 5.8 ± 6.7 3.0 0.002
Physical limitations 4.3 ± 6.5 0.0 4.6 ±5.6 5.0 NS
Pain 3.9 ± 2.0 4.0 3.8 ± 2.1 4.0 NS
General health 
status
11.0 ± 3.3 11.0 9.7 ± 2.3 10.0 NS
Physical aspect  
of quality of life
30.5 ± 14.7 29.0 24.0 ± 12.1 20.5 NS
Vitality 8.8 ± 3.5 9.0 8.7 ± 3.2 8.0 NS
Emotional limita-
tions
3.9 ± 5.8 0.0 2.5 ± 5.0 0.0 NS
Social functioning 2.5 ± 2.0 3.0 2.1 ± 1.6 2.0 NS
Psychical health 
status
10.3 ± 7.2 9.0 9.2 ± 4.1 9.5 NS
Psychical aspect  
of quality of life
25.5 ± 14.5 22.0 22.5 ± 10.6 21.0 NS
Quality of life index 56.0 ± 25.1 53.0 46.5 ± 18.7 46.5 NS
*Level of statistical significance was adopted at p < 0.05; SD — standard deviation; p — level of significance; NS — not statistically significant
Table 4. Quality of sexual life assessed by Female Sexual Function Index (FSFI) in study group versus control group
Domain Study group Control group p (Mann-Whitney 
U test)*Mean value ± SD Median value Mean value ± SD Median value
Desire 3.0 ± 0.9 3.0 3.9 ± 0.7 3.6 < 0.001
Arousal 3.6 ± 1.8 4.2 4.3 ± 1.4 4.7 0.033
Lubrication 4.1 ± 2.1 4.8 5.1 ± 1.6 5.9 0.003
Orgasm 4.1 ± 2.1 4.8 4.9 ± 1.6 5.2 NS
Satisfaction 4.1 ± 2.1 4.8 4.9 ± 1.7 5.6 NS
Pain 4.5 ± 2.3 6.0 5.2 ± 1.8 6.0 NS
FSFI total 23.4 ± 10.4 27.2 28.3 ± 7.8 30.8 0.005
*Level of statistical significance was adopted at p < 0.05; SD — standard deviation; p — level of significance; NS — not statistically significant
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vs. 55.1%). Moreover, no correlation was found between 
FSD and arterial hypertension, diabetes or dyslipidemia.
We found no direct impact of dietary habits on sexual 
dysfunction, whereas Esposito et al. [18] and Giugliano et al. 
[19] came to quite opposite conclusions. The former study 
showed that following Mediterranean diet for two years had 
a beneficial influence on general health status, and decrea-
sed prevalence of both metabolic syndrome and female se-
xual dysfunction. Authors of the latter study analyzed dietary 
habits, and observed that obesity, metabolic syndrome and 
arterial hypertension were least prevalent, dyslipidemias le-
ast pronounced, and diabetes best compensated in females 
following diet most compatible with Mediterranean model. 
These patients were most sexually active (65.1% vs. 54.2%, 
p = 0.01), and had fewer sexual dysfunctions as compared 
to control group (47.6% vs. 57.8%, p = 0.01).
There was no significant difference in quality of life of 
patients with metabolic syndrome when compared to he-
althy counterparts in our study. Of note, patients in study 
group had higher scores than control group (56.0 ± 25.1 vs. 
46.5 ± 18.7), which in Polish version of the questionnaire 
reflects a poorer quality of life. Patients with metabolic 
syndrome reported significantly poorer physical functioning.
Conclusions
1. Female patients with metabolic syndrome eat fewer 
meals per day but have a greater total caloric consumption 
as compared to women not having metabolic conditions. 
2. No significant correlation was found between total 
caloric value, percentage of TCV from respective food 
components, and quality of sex life or occurrence of sexual 
dysfunction in study group or healthy controls. 3. There was 
no difference in quality of life evaluated by patients with 
metabolic syndrome or healthy controls. Quality of life was 
not influenced by total caloric value and diet composition, 
neither in patients with metabolic syndrome nor in healthy 
female controls. 4. Women with metabolic syndrome were 
less physically active, and had less satisfactory sexual life 
than females with normal metabolic function. 5. Female 
patients with metabolic syndrome more often experien-





Wstęp. Zespół metaboliczny należy do czynników ryzyka chorób układu sercowo-naczyniowego i można go rozpoznać na-
wet u co 4. dorosłego obywatela świata. W świetle znacznego rozpowszechnienia zaburzeń funkcji seksualnych u kobiet 
(19–63%) pojawia się pytanie, czy istnieje związek między zespołem metabolicznym a zaburzeniami funkcji seksualnych 
w tej grupie oraz jaki wpływ na ich występowanie może mieć sposób odżywiania.
Materiał i metody. W badaniu wzięło udział 99 regularnie miesiączkujących kobiet; 71 z zespołem metabolicznym (grupa 
badana) i 28 kobiet bez zespołu metabolicznego (grupa kontrolna). Wykonano badanie podmiotowe, pomiary antropo-
metryczne oraz ciśnienia tętniczego; oznaczono parametry biochemiczne w surowicy krwi. Pod względem jakościowym 
i ilościowym oceniono 3-dniowy jadłospis, a także kwestionariusze dotyczące życia intymnego i jakości życia.
Wyniki. Badane grupy były jednorodne pod względem wieku. Kobiety w grupie badanej spożywały mniejszą liczbę 
posiłków w ciągu dnia o większej łącznej wartości energetycznej (1959 ± 501 kcal v. 1556 ± 219 kcal; p < 0,05). Ko-
biety z zespołem metabolicznym rzadziej deklarowały aktywne życie seksualne i czuły się mniej atrakcyjne seksualnie. 
W analizie potrzeb i reakcji seksualnych Mell-Krat uzyskiwały mniej punktów (44,6 ± 12,5 v. 56,2 ± 5,7; p < 0,001), co 
znaczy, że częściej występowały u nich zaburzenia sfery seksualnej; podobnie w skali FSFI (23,4 ± 10,4 v. 28,3 ± 7,8; 
p = 0,005). Na podstawie wyników kwestionariusza SF-36 nie wykazano różnic pod względem wskaźnika jakości życia 
między grupami.
Wnioski. 1. Kobiety z zespołem metabolicznym spożywają w ciągu doby mniej posiłków o łącznej większej kaloryczności. 
2. Kobiety z zespołem metabolicznym mają mniej aktywne i mniej satysfakcjonujące życie seksualne niż kobiety bez 
zespołu metabolicznego oraz częściej doświadczają zaburzeń w sferze seksualnej. 3. Jakość życia kobiet z zespołem 
metabolicznym nie różni się od jakości życia kobiet bez zespołu metabolicznego. 4. Nie wykazano związku między 
sposobem odżywiania a jakością życia, jakością życia seksualnego ani występowaniem zaburzeń funkcji seksualnych.
Słowa kluczowe: seksualność, zaburzenia funkcji seksualnych, zespół metaboliczny, jakość życia, dieta
(Folia Cardiologica 2015; 10, 4: 251–257)
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Problem zaburzeń funkcji seksualnych u kobiet, biorąc pod uwagę dostępne piśmienni-
ctwo, jest rzadziej podejmowany od tematu zaburzeń funkcji seksualnych u mężczyzn. 
Może to wynikać ze złożoności zagadnienia i trudności z oceną tych zaburzeń w porów-
naniu z zaburzeniami u mężczyzn. Problemy z erekcją są ogólnie najczęściej poruszanym 
w piśmiennictwie tematem zaburzeń tej sfery. Podawana przez różnych autorów częstość 
występowania zaburzeń funkcji seksualnych u kobiet i duże rozbieżności częstości wy-
stępowania tego problemu (19–71%) w poszczególnych pracach wskazują, że dalsze 
opracowania są niezbędne. Artykuł pt. „Seksualność kobiet z zespołem metabolicznym” 
Jowity Szeligowskiej, Sylwii Skorupskiej, Marcina Wełnickiego i Artura Mamcarza stano-
wi istotny wkład merytoryczny w badania nad zaburzeniami funkcji seksualnych kobiet 
polskiej populacji i jest jedną z niewielu prac poświęconych tym zaburzeniom w okresie 
przed menopauzą, zwłaszcza że uwzględnia subpopulację kobiet z zespołem metabo-
licznym.
Według danych uzyskanych z polskiego programu WOBASZ kryteria rozpoznania zespołu 
metabolicznego spełnia przeszło 1/4 populacji badanych kobiet. Poza zwiększaniem 
ryzyka chorób układu sercowo-naczyniowego znany jest negatywny wpływ zespołu meta-
bolicznego na funkcje seksualne. Kiedyś uznawano, że zaburzenia funkcji seksualnych 
mają przede wszystkim podłoże psychiczne i powinny być leczone przez seksuologów, 
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psychiatrów czy psychologów. Jednak inne prace dotyczące tego tematu wskazują, że zaburzenia te mają w dużej mie-
rze charakter organiczny. Negatywny wpływ na funkcje seksualne czynników składających się na rozpoznanie zespołu 
metabolicznego — zarówno u kobiet, jak i u mężczyzn — jest generalnie znany, ale niezbyt dokładnie poznany. Wpływ 
ten wynika przede wszystkim z towarzyszących zespołowi metabolicznemu zmian hormonalnych, stanu zapalnego 
i postępującej miażdżycy naczyń. W badanej w omawianej pracy populacji kobiet z zespołem metabolicznym wyniki 
uzyskiwane za pomocą poszczególnych kwestionariuszy służących ocenie funkcji seksualnych były jednoznacznie 
gorsze niż u kobiet bez zespołu metabolicznego. Wynika z tego, że jednym z celów terapii pacjentek z zespołem me-
tabolicznym powinna być także poprawa w zakresie funkcjonowania seksualnego. Ciekawym aspektem omawianych 
badań jest wpływ zespołu metabolicznego i zaburzeń funkcji seksualnych na jakość życia — wszak sfera seksualności 
człowieka jest jednym z głównych czynników wpływających na tę jakość. W komentowanej pracy nie stwierdzono jednak 
takiego wpływu u kobiet z zespołem metabolicznym w porównaniu z grupą kontrolną, choć między innymi kobiety z tym 
zespołem czuły się mniej atrakcyjne seksualnie i relacjonowały istotnie gorsze funkcjonowanie fizyczne. Także dieta 
w populacji kobiet z grup badanej i kontrolnej zasadniczo się różniła. Rzadsze spożywanie posiłków, ale o zwiększonej 
kaloryczności, w grupie pacjentek z zespołem metabolicznym dopełnia obrazu osoby z zaburzeniami metabolicznymi, 
które sprzyjają rozwojowi chorób układu sercowo-naczyniowego.
Różnice we wnioskach w poszczególnych badaniach dotyczących omawianego tematu, w tym w przytaczanym ba-
daniu Esposito i wsp., zapewne wynikają ze złożoności problemu samego zespołu metabolicznego, liczby czynników 
wpływających na kryteria rozpoznania oraz odmienne populacje badane, a co za tym idzie — różnice kulturowe (co 
ma znaczenie przy udzielaniu odpowiedzi w badaniach kwestionariuszowych). Ciekawe, do jakich wniosków dopro-
wadziłoby porównanie profilu hormonów płciowych u pacjentek z dokonanym rozpoznaniem zespołu metabolicznego 
i bez tego rozpoznania w populacji kobiet uczestniczących w badaniu oraz czy zauważalny byłby wpływ ewentualnych 
różnic na funkcjonowanie seksualne — takie zależności są omawiane w piśmiennictwie. Wyniki badania wskazują, że 
u pacjentki z zespołem metabolicznym, w porównaniu z kobietą niespełniającą kryteriów rozpoznania tego zespołu, 
nie tylko zmieniają się masa ciała, obwód talii, ciśnienie tętnicze, stężenie lipidów czy glikemia, ale również pogarsza 
się funkcjonowanie seksualne. Warto o tym pamiętać, lecząc kolejną pacjentkę z zespołem metabolicznym, na przy-
kład z powodu nadciśnienia tętniczego, w poradni czy na oddziale kardiologicznym. Ten interesujący temat wymaga 
z pewnością dalszych, pogłębionych badań.
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